Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 liberty asthma quest study

Dupilumab, a fully human interleukin (IL)-4 receptor- α monoclonal antibody inhibiting IL-4/IL-13 signaling pathways, key drivers of Type 2 inflammation, is approved for treating adults with inadequately controlled moderate-to-severe atopic dermatitis. In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), dupilumab 200mg and 300mg administered ever y 2 weeks versus matched placebo reduced annualized severe exacerbation rates and improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) and quality-of-life measures, and was generally well tolerated in patients with uncontrolled, moderate-to-severe asthma (≥12 years, without mini mum baseline Type 2 inflammatory biomarkers).

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Castro, J. Corren, N. Hanania, I. Pavord, S. Quirce, K. Thangavelu, M. Rice, T. O'Riordan, J. Maroni, P. Rowe, Y. Lu, N. Amin, M. Ruddy, B. Akinlade, N. Graham, A. Teper Tags: A206 Source Type: research